Astellas Pharma Inc. – OTC:ALPMY
Astellas Pharma stock price today
$11.51
+1.83
+19.03%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Astellas Pharma stock price monthly change
-7.55%
month
Astellas Pharma stock price quarterly change
-7.55%
quarter
Astellas Pharma stock price yearly change
-17.63%
year
Astellas Pharma key metrics
Market Cap | 26.69B |
Enterprise value | 3.42T |
P/E | 157.64 |
EV/Sales | 2.01 |
EV/EBITDA | 15.44 |
Price/Sales | 1.60 |
Price/Book | 1.63 |
PEG ratio | 0.06 |
EPS | -15.77 |
Revenue | 1.41T |
EBITDA | 300.36B |
Income | -26.92B |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 1.02% |
Oper. margin | 9.82% |
Gross margin | 76.24% |
EBIT margin | 9.82% |
EBITDA margin | 21.25% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAstellas Pharma stock price history
Astellas Pharma stock forecast
Astellas Pharma financial statements
| Dec 2021 | 340.62B | 60.88B | 17.87% |
|---|---|---|---|
| Mar 2022 | 303.87B | -8.40B | -2.77% |
| Mar 2023 | 354.25B | -46.12B | -13.02% |
| Mar 2024 | 414.60B | -33.27B | -8.03% |
| 2026 | 1.62T | 115.04B | 7.09% |
|---|---|---|---|
| 2027 | 1.74T | 183.29B | 10.51% |
| 2028 | 1.73T | 218.63B | 12.61% |
| 2029 | 1.51T | 142.85B | 9.41% |
Analysts Price target
Financials & Ratios estimates
Paying a dividend greater than earnings.
4.39%
Yield TTM
| Payout ratio | 722.19% |
|---|
| 2020 | 2.39% |
|---|---|
| 2021 | 2.4% |
| 2022 | 2.43% |
| 2023 | 2.93% |
| 2024 | 3.97% |
| Sep 2022 | 2583661000000 | 934.14B | 36.16% |
|---|---|---|---|
| Dec 2022 | 2513948000000 | 943.52B | 37.53% |
| Mar 2023 | 2456518000000 | 948.56B | 38.61% |
| Mar 2024 | 3569603000000 | 1.97T | 55.29% |
| Dec 2021 | 69.73B | 7.90B | -51.32B |
|---|---|---|---|
| Mar 2022 | 48.75B | -14.99B | -75.03B |
| Mar 2023 | 118.06B | -25.19B | -104.50B |
| Mar 2024 | 74.55B | -24.73B | 30.92B |
Astellas Pharma alternative data
| Aug 2023 | 14,484 |
|---|---|
| Sep 2023 | 14,484 |
| Oct 2023 | 14,484 |
| Nov 2023 | 14,484 |
| Dec 2023 | 14,484 |
| Jan 2024 | 14,484 |
| Feb 2024 | 14,484 |
| Mar 2024 | 14,484 |
| Apr 2024 | 14,484 |
| May 2024 | 14,484 |
| Jun 2024 | 14,484 |
| Jul 2024 | 14,754 |
Astellas Pharma other data
Voyager: Crossing The Blood-Brain Barrier, Competitors, And Investment Relevance
Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart
Sangamo: Pipeline Expansion Via Partnership And Internal ST-503 Development
Week In Review: $1.7B Collaboration Between Elpiscience And Astellas Is Final 2023 Deal
ESSA Pharma: Unique N-Terminal Domain Approach Might Hinder mCRPC Resistance
Ironwood Pharmaceuticals: The Right Play Now
Merck Stock Not Likely To Be Saved By Dividends
Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas
Apellis Pharmaceuticals: Maintain 'Buy' Following Astellas' $5.9 Billion Acquisition Of Iveric Bio
-
What's the price of Astellas Pharma stock today?
One share of Astellas Pharma stock can currently be purchased for approximately $11.51.
-
When is Astellas Pharma's next earnings date?
Unfortunately, Astellas Pharma's (ALPMY) next earnings date is currently unknown.
-
Does Astellas Pharma pay dividends?
Yes, Astellas Pharma pays dividends and its trailing 12-month yield is 4.4% with 722% payout ratio.It means that the company is paying a dividend greater than earnings. The last Astellas Pharma stock dividend of $0 was paid on 6 Sep 2025.
-
How much money does Astellas Pharma make?
Astellas Pharma has a market capitalization of 26.69B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 5.6% to 1.6T US dollars.
-
What is Astellas Pharma's stock symbol?
Astellas Pharma Inc. is traded on the OTC under the ticker symbol "ALPMY".
-
What is Astellas Pharma's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers—General industry.
-
How do i buy shares of Astellas Pharma?
Shares of Astellas Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Astellas Pharma have?
As Jul 2024, Astellas Pharma employs 14,754 workers, which is 2% more then previous month and 2% more then previous quarter.
-
When Astellas Pharma went public?
Astellas Pharma Inc. is publicly traded company for more then 6 years since IPO on 30 Nov 2018.
-
What is Astellas Pharma's official website?
The official website for Astellas Pharma is astellas.com.
-
How can i contact Astellas Pharma?
Astellas Pharma can be reached via phone at +81 3 3244 3000.
Astellas Pharma company profile:
Astellas Pharma Inc.
astellas.comExchange:
OTC
Full time employees:
14,522
Industry:
Drug Manufacturers—General
Sector:
Healthcare
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals in the Japan, United States, and internationally. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of overactive bladder urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
2-5-1, Nihonbashi-Honcho
Tokyo, 103-8411
Tokyo, 103-8411
:
ISIN: US04623U1025
:
